Compare DNUT & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | AURA |
|---|---|---|
| Founded | 1937 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.4M | 713.4M |
| IPO Year | 2021 | 2021 |
| Metric | DNUT | AURA |
|---|---|---|
| Price | $3.53 | $7.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.15 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.9M | 661.7K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,522,616,000.00 | N/A |
| Revenue This Year | $0.55 | N/A |
| Revenue Next Year | $3.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.88 | $4.73 |
| 52 Week High | $5.73 | $9.54 |
| Indicator | DNUT | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 63.14 |
| Support Level | $3.13 | $5.18 |
| Resistance Level | $3.66 | $7.81 |
| Average True Range (ATR) | 0.22 | 0.50 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 10.34 | 99.37 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.